Latest News

STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval

What does it all mean now that the Food and Drug Administration has issued a surprise decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug Vyondys 53, reversing its surprise decision to reject the drug in August?

Here are some thoughts and observations about the latest twist in the always twisty Sarepta story, including potential implications for Biogen and its controversial Alzheimer’s drug.

Continue to STAT Plus to read the full story…

Source link

Related posts

STAT Plus: Once again, lawmakers introduce a bill to end tax breaks for consumer drug ads. Will it work this time?


48-Hour Fasting Benefits And Risks: Everything To Know


US Births Plunge To 32-Year Low; Record Slump In Birth Rate Continues


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy